Creatine Supplementation and Resistance Training to Improve Sarcopenia Parameters in Patients With Prostate Cancer After Androgen Deprivation Therapy
The Effect of Creatine Supplementation Associated With Resistance Training on Sarcopenia Parameters and Muscle Density in Prostate Cancer Patients After Androgen Deprivation Therapy
University of Sao Paulo
34 participants
May 1, 2026
INTERVENTIONAL
Conditions
Summary
This randomized, double-blind, placebo-controlled clinical trial will investigate the effects of creatine supplementation combined with a 12-week supervised resistance training program on muscle mass, muscle strength, physical performance (e.g., parameters of sarcopenia), and muscle density in men with prostate cancer undergoing androgen deprivation therapy (ADT). ADT often causes loss of lean mass, reduced muscle strength, functional impairment, and increased fat mass. Eligible male patients will be randomly assigned to receive either creatine monohydrate or a placebo (maltodextrin) in a double-blind manner, in addition to participating in the resistance exercise program. Assessments will be performed at baseline and after the 12-week intervention period and will include: * Muscle density and architecture assessed by ultrasound * Body composition (lean mass and fat mass) * Muscle strength * Physical performance (functional performance tests) * Inflammatory biomarkers * Vascular function parameters The primary goal is to assess whether creatine supplementation combined with resistance training can safely improve muscle quality and quantity, strength, and physical function in these patients. If effective and safe, the intervention could help reduce muscle loss and improve quality of life in men undergoing ADT.
Eligibility
Inclusion Criteria8
- Men aged ≥ 40 years;
- Patients with histologically or cytologically confirmed localized prostate cancer;
- Patients who have undergone surgical castration or pharmacological castration with gonadotropin-releasing hormone (GnRH/LHRH) agonists or antagonists for at least six months prior to the start of the intervention;
- Patients receiving continuous or intermittent androgen deprivation therapy;
- Patients with an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2;
- Not engaged in resistance training in the three months prior to the intervention;
- Not using creatine supplementation in the three months prior to the intervention;
- Willing to participate in a 12-week intervention consisting of resistance training performed three times per week and daily supplementation with creatine monohydrate or maltodextrin.
Exclusion Criteria6
- Patients with insulin-dependent diabetes mellitus;
- Patients with dialysis-dependent renal failure;
- Patients with severe chronic liver disease;
- Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m²;
- Any hormonal treatment outside that established by the medical team;
- Patients planning to undergo chemotherapy within the next six months.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will receive 5 g/day of creatine monohydrate throughout the 12-week supervised resistance training program.
Participants will receive 5 g/day of maltodextrin, matched in appearance and caloric content to creatine, throughout the 12-week supervised resistance training program.
Participants will complete a 12-week supervised, progressive resistance training program designed to improve muscle strength and muscle mass. Training sessions will be conducted under professional supervision and will occur three times per week. The program will target major muscle groups of the upper and lower body using weight machines and free weights. All participants in both study arms will follow the same resistance training protocol.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07463092